Released May 9, 2017, after the close
10-Q filed May 9, 2017, 39 days after period end · 0001232524-17-000111
Q1 2017 · 10-Q
Revenue$376.05M$376.05M +11.9% vs Q1 2016−5.2% vs Q4 2016
Net Income$86.51M$86.51M +14.1% vs Q1 2016−25.9% vs Q4 2016
EPS Diluted$1.41$1.41 +16.5% vs Q1 2016−26.2% vs Q4 2016
Gross Profit$348,613,000+12.3%
Operating Income$136,140,000+12.4%
Operating Cash Flow$164,540,000+8.5%
Free Cash Flowderived$160,966,000+7.9%
Margins · derived
Gross margin92.7%+0.3 pt vs Q1 2016
Operating margin36.2%+0.1 pt vs Q1 2016
Net margin23.0%+0.4 pt vs Q1 2016
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2017 | Q1 2016 | Q1 2015 | Q1 2014 |
|---|---|---|---|---|
| Revenue | $376.05M | $336.01M | $309.30M | $246.92M |
| Net Income | $86.51M | $75.81M | $70.70M | -$92.65M |
| EPS Diluted | $1.41 | $1.21 | $1.12 | -$1.58 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR